Nomura Note Provides Another Spark for Micron Stock

Nomura set a high bar for Micron stock

Mar 12, 2018 at 2:44 PM
facebook twitter linkedin

It's been a volatile day for stocks, with the Dow exploring a 282-point range on both sides of breakeven, but lower at last check. Among individual names making notable moves are semiconductor stock Micron Technology, Inc. (NASDAQ:MU), financial giant Goldman Sachs Group Inc (NYSE:GS), and biotech Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Here's a quick look at how shares of MU, GS, and MACK are trading today.

Overbought MU Stock Sets Fresh High

Micron stock is hot yet again, last seen trading up 8.7% at $59.35, tapping another 17-year high of $61.17 earlier in the session. Today's bull gap comes after a price-target hike at Nomura to $100 -- almost double its previous target, and the highest on the Street. The brokerage firm sees a number of positives in the future for the stock, including expectations for a dividend increase at the company's investor day in May. MU shares were trading around $25 at this time last year, and have gained 47% in just the past month. The equity is technically overbought, going by its 14-day Relative Strength Index (RSI) of 80,  but sector tailwinds could make it hard to bet against Micron.

Call Buyers Bet On Red-Hot GS Stock

Goldman Sachs stock is trading up 1.1% at $273.86 -- the best Dow stock so far -- after the company may have hinted David Solomon will be its new CEO by announcing fellow co-Chief Operating Officer Harvey Schwartz is leaving the bank. In fact, GS shares earlier touched a record high of $275.31, gaining well north of 23% in the past six months alone.

Call traders have certainly jumped aboard, judging by data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Goldman's 10-day call/put volume ratio is 2.23 across those exchanges, ranking in the 84th annual percentile.

Another Big Drop For MACK Stock

Wall Street is clearly unimpressed with Merrimack's business update, which revealed plans to include the number of participants in the company's non-small cell lung cancer study. A price-target cut from $12 to $15 are also putting pressure on MACK shares, which are trading down 10% at $10.42 -- continuing the weak price action they've displayed for over a year. This underperformance has drawn the attention of short sellers, who control 13.5% of the total float. Going by average daily volumes, it would take these short sellers more than three weeks to cover their positions.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!